-
Company Insights
Innovation and Patenting activity of PharmaEssentia Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of PharmaEssentia Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2B LA in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2B LA in Myelofibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2B LA in Myelofibrosis Drug Details: Ropeginterferon alpha-2b (Besremi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2B LA in Hepatitis C
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2B LA in Hepatitis C report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2B LA in Hepatitis C Drug Details: Ropeginterferon...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2B LA in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2B LA in Hepatitis B report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2B LA in Hepatitis B Drug Details: Ropeginterferon...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2b LA in Essential Thrombocythemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2b LA in Essential Thrombocythemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2b LA in Essential Thrombocythemia Drug Details: Ropeginterferon alpha-2b...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2B LA in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2B LA in Hepatitis D report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2B LA in Hepatitis D Drug Details: Ropeginterferon...
-
Product Insights
Actinic (Solar) Keratosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Actinic (Solar) Keratosis - Drugs In Development, 2023’, provides an overview of the Actinic (Solar) Keratosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Essential Thrombocythemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Essential Thrombocythemia - Drugs In Development, 2023’, provides an overview of the Essential Thrombocythemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Essential Thrombocythemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Polycythemia Vera – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycythemia Vera - Drugs In Development, 2023’, provides an overview of the Polycythemia Vera pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chemotherapy Induced Anemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Anemia - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Anemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...